Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Travoprost/timolol.

Sheridan M Hoy1, Susan J Keam, Gillian M Keating

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|August 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025
Same journal

Correction: Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice.

Drugs & aging·2026
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
See all related articles

This study shows that once-daily travoprost/timolol eyedrops effectively lower intraocular pressure (IOP) for glaucoma patients. It is well-tolerated and comparable to other combination therapies.

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Open-angle glaucoma and ocular hypertension require effective intraocular pressure (IOP) management.
  • Fixed-combination eyedrops offer a convenient dosing regimen for patients.
  • Travoprost (prostaglandin analogue) and timolol (beta-blocker) are established IOP-lowering agents.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a fixed combination of travoprost 0.004% and timolol 0.5% (travoprost/timolol) for once-daily use.
  • To compare travoprost/timolol with monotherapy and other combination therapies in managing intraocular pressure.

Main Methods:

  • Randomized, well-designed clinical studies were conducted.
  • Efficacy was assessed by measuring intraocular pressure (IOP) reduction.
  • Tolerability was evaluated by monitoring adverse events.

Related Experiment Videos

Main Results:

  • Once-daily travoprost/timolol demonstrated efficacy similar to concurrent travoprost and timolol, and superior to monotherapy.
  • Travoprost/timolol maintained IOP control and was noninferior to latanoprost/timolol.
  • The fixed combination was generally well tolerated, with a similar profile to monotherapy and other combinations.

Conclusions:

  • Travoprost/timolol is an effective and well-tolerated option for managing open-angle glaucoma and ocular hypertension.
  • The fixed combination provides a convenient once-daily treatment with comparable efficacy to existing therapies.
  • Most adverse events, such as ocular hyperemia, were mild and transient.